Close Menu

leukemia

China's National Medical Products Administration granted conditional approval based on results from a Phase III study in FLT3-mutated AML patients.

The TuPro study will evaluate whether a comprehensive suite of routine and emerging tests can add value to treatment decision making and improve outcomes.  

Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.

Researchers aim to evaluate the safety and tolerability of the CD19-specific T cells manufactured using Ziopharm's Rapid Personalized Manufacturing process.

An independent data monitoring committee recommended terminating the study and Astellas has stopped enrollment after the drug failed to meet its primary endpoint.

A range of drugs from Agios' cancer pipeline will be transferred to Servier, including two commercial drugs Tibsovo and Idhifa.

In a retrospective analysis, ALL patients tested with NGS were less likely to achieve MRD-negative status than when tested with flow cytometry.

Researchers presented data exploring CLL patients' outcomes on fixed-duration combination regimens and on using uMRD to decide which patients can stop treatment.

The study found that being Black was an independent predictor of poor survival and suggested that mutation status in genes such as NPM1 may play a role in the disparities.

The company received permission from regulators in China to study the agent APG-115 in T-PLL, a rare leukemia characterized by an ATM mutation in most cases.

Pages